A quantitative systems toxicology model assessed liver effects of CBD and valproate individually and combined, finding increased ALT elevation risk with co-administration.
Neurologists, pharmacologists, epilepsy patients on valproate considering CBD, and drug safety researchers.
ALT >3x ULNCombined CBD and valproate increased risk of clinically significant liver enzyme elevations
What the researchers found
Using quantitative systems toxicology modeling, the study found that combined CBD and valproate use increased the incidence of ALT elevations above clinical thresholds compared to either drug alone, helping explain clinical observations of hepatotoxicity.
Why it matters
Many epilepsy patients taking valproate also use or consider CBD, and understanding the liver safety profile of this combination is critical for clinical decision-making.
The numbers in context
In CBD clinical trials, ALT elevations greater than 3 times the upper limit of normal were observed in some patients, with higher incidence when combined with valproate.
How the study worked
Quantitative systems toxicology (QST) modeling to simulate liver effects of CBD, valproate, and their combination.
Who was studied
Computational simulation based on clinical trial data from patients with epilepsy treated with CBD and/or valproate.
What this study cannot tell us
Computational modeling may not capture all biological complexity; model predictions need clinical validation; individual patient factors affecting hepatotoxicity are difficult to fully incorporate.
How to read the evidence
Quantitative systems toxicology modeling provides mechanistic insights; based on clinical data but predictions need further validation.
When this study was published
Recent study using advanced computational modeling approaches.
The bigger picture
This type of computational safety modeling represents an important advance in predicting drug-drug interactions, particularly relevant as CBD becomes more widely used alongside existing medications.
Replication
Model findings consistent with clinical trial observations of hepatotoxicity with CBD-valproate co-administration.
Funding
Not specified
Conflicts of interest
Not specified
Questions still open
- What is the mechanism of the CBD-valproate liver interaction?
- At what doses does the interaction become clinically significant?
- Can liver monitoring protocols mitigate the risk?
Read the original research
Assessing Liver Effects of Cannabidiol and Valproate Alone and in Combination Using Quantitative Systems Toxicology.
Clinical pharmacology and therapeutics, 114(5), 1006-1014
Citation
Lakhani, Vinal V; Generaux, Grant; Howell, Brett A; Longo, Diane M; Watkins, Paul B. (2023). Assessing Liver Effects of Cannabidiol and Valproate Alone and in Combination Using Quantitative Systems Toxicology.. Clinical pharmacology and therapeutics, 114(5), 1006-1014. https://doi.org/10.1002/cpt.3004